Combined SGLT2 Inhibitors And Finerenone Therapy For Cardio-Renal Protection
International Journal of Drug Delivery Technology · 25.05.2026 · 16 (36s)
DOI: 10.25258/ijddt.16.36s.95 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, erschienen am 25.05.2026. Verfasst von Ernst Louis und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
The paper was developed to determine the perceptions, awareness, and clinical attitudes of healthcare professionals in using SGLT2 inhibitors and Finerenone in cardio-renal protection as a combination treatment. This combination therapy has been observed to be effective in the management of chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD). The study will examine the effects of demographics on the acceptance and the readiness to implement this therapy.
Methods
A full cross-sectional study was used in a quantitative study, with a sample population of 238 healthcare professionals (nephrologists, cardiologists, endocrinologists, and clinical pharmacists). To evaluate the data, a structured Likert-scale questionnaire was employed, which aims at gathering such data as demographics, knowledge of clinical practices, perceived efficacy, and readiness to implement. The data was analyzed with the help of descriptive statistics, reliability tests (Cronbach's Alpha), tests of normality (Shapiro-Wilk), validity (KMO and Bartlett test), inferential tests (Independent Samples ttest, One-Way ANOVA, Kruskal-Wallis, Chi-square), and regression analysis to determine the relationship between demographic and perceptions towards therapy.
Results
The use of parametric tests was justified because the results of the normality Shapiro-Wilk test (p > 0.05) showed that all items in the questionnaire were normally distributed. Cronbach's Alpha Coefficient Reliability = 0.912. This provided superior internal consistency. The fact that the KMO value of the validity was found to be adequate (KMO = 0.812) and the variance of the Bartlett Test (χ² = 745.326, p = 0.001) proved that the data were adequate to conduct factor analysis. Inferential Tests: Independent Samples t-Test showed a significant difference between males and female respondents (t = 2.736, p = 0.007). One-Way ANOVA revealed that there were some significant differences between age groups (F = 4.862, p = 0.003). Based on the Kruskal-Wallis Test, the changes in perceptions were found to be different according to qualification (H = 12.457, p = 0.002). Chi-Square Test demonstrated that there was a significant relation between gender and qualifications (χ² = 18.325, p = 0.001). Pearson Correlation: strong correlations were observed between the items in the questionnaires (r = 0.60 to 0.95), indicating that there were similar impressions of the therapy between the respondents. Regression Analysis: Gender (β = 0.214, p = 0.003), age (β = 0.368, p = 0.001), and experience (β = 0.421, p < 0.001) were all significant predictors of perceptions towards the therapy, with higher acceptance being observed in older, more experienced professionals.
Conclusion
The gender, age, and experience of healthcare professionals play a major role in determining the adoption of the combined therapy of SGLT2 inhibitors and Finerenone. The research demonstrates the necessity of specific educational interventions to make people more aware of this therapy and its implementation. The results can be discussed as an addition to the existing body of data on the clinical use of cardio-renal therapies and indicate that the customized methods may contribute to the increase in the adoption of novel treatment methods within the healthcare framework.
Zitieren
APA
Louis, E., Bangash, S. A., & Kharal, A. A. (2026). Combined SGLT2 Inhibitors And Finerenone Therapy For Cardio-Renal Protection. International Journal of Drug Delivery Technology, 16(36s). https://doi.org/10.25258/ijddt.16.36s.95
Vancouver
Louis E, Bangash SA, Kharal AA. Combined SGLT2 Inhibitors And Finerenone Therapy For Cardio-Renal Protection. International Journal of Drug Delivery Technology. 2026;16(36s). doi:10.25258/ijddt.16.36s.95
BibTeX
@article{Louis2026,
author = {Louis, Ernst and Bangash, Sudhair Abbas and Kharal, Ahmad Abubakr},
title = {Combined SGLT2 Inhibitors And Finerenone Therapy For Cardio-Renal Protection},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {36s},
doi = {10.25258/ijddt.16.36s.95}
}
EUVIMED